For blood products such as albumin and globulin preparations, preparations containing albumin (such as urokinase and interferon), fat emulsions, and preparations containing fat emulsions (such as propofol), the package insert states, "Discard residual solution after the package has been used." This injunction is based on the speculation that if these preparations rich in nutrients are contaminated with microorganisms, the contaminants will proliferate rapidly. However, there have been only a few studies on the viability of microorganisms in these preparations. [1] [2] [3] In terms of resource conservation, the use of residual solution after the package has been used is desirable. Therefore to determine whether these preparations are safe to use again after the package has been used once, we evaluated the viability of various microbial species in these preparations.
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MATERIALS AND METHODS
The five microorganism species used for viability tests in various types of preparations were Serratia marcescens IFO 3736, one strain of Burkholderia cepacia isolated from inhalation solution, Pseudomonas aeruginosa IFO 3919, Staphylococcus aureus 209P, and Candida albicans IFO 1386. All strains except for B. cepacia were purchased from the Institute for Fermentation (Osaka, Japan). B. cepacia was isolated from inhalation solution in use (dibekacin/betamethasone solution). 4) Stock cultures of S. marcescens, B. cepacia, P. aeruginosa, and S. aureus were maintained on trypticase soy agar (Eiken Chemical, Tokyo, Japan) at 4°C, and stock culture of C. albicans on sabouraud dextrous agar (Eiken Chemical) at 4°C.
S. marcescens, B. cepacia, P. aeruginosa, and S. aureus were incubated on trypticase soy agar at 30°C for 48 h, harvested, and suspended with sterile physiological saline to obtain about 10 8 viable cells/ml. C. albicans was incubated on sabouraud dextrose agar at 30°C for 48 h, harvested, and suspended with sterile physiological saline to obtain about 10 8 viable cells/ml. About 10 8 viable cells/ml of each strain were diluted in sterile physiological saline to obtain about 10 5 viable cells/ml, and an aliquot (50 ml) of this microbial solution was inoculated into 950 ml of each preparation and swirled for 10 s. The samples were incubated at 7 and 30°C. Plate counts were performed at 8, 24, and 48 h and 7 d. This experiment was performed twice, and the mean viable count was calculated.
The viability of S. marcescens and B. cepacia at 30°C in eight preparations containing albumin or fat emulsions was evaluated. The viability of S. marcescens, B. cepacia, P. aeruginosa, S. aureus, and C. albicans at 7 and 30°C was evaluated in six globulin preparations. Table 1 shows the evaluated preparations, the names and concentrations of additive contents in these preparations, and the pH and osmolarity of these preparations. Of six globulin preparations evaluated, four contained 1-2.5% glycine to prevent protein degradation. Figure 1 shows the viability of S. marcescens and B. cepacia at 30°C in three albumin preparations. Both S. marcescens and B. cepacia proliferated rapidly in each albumin preparation. Figure 2 shows the viability of S. marcescens and B. cepacia at 30°C in six globulin preparations. Both bacterial species proliferated rapidly in globulin preparations without glycine (Polyglobin-N, Venoglobulin-IH). However, in globulin preparations containing glycine (Gamma-Venin P, Venilon-I, Globulin Injection, and Ahlbulin), no growth of S. marcescens was observed over 24 h after its addition, while the viable counts of B. cepacia decreased slowly over 7 d. Although not shown in Fig. 2 , the viable counts of P. aeruginosa, S. aureus, and C. albicans decreased slowly in globulin preparations at 30°C over 7 d. At 7°C, no growth of S. marcescens, B. cepacia, P. aeruginosa, C. albicans, and S. aureus was detected over 7 d. Figure 3 shows the viability of S. marcescens and B. cepacia at 30°C in albumin-containing preparations such as urokinase and interferon. Both bacterial species also proliferated rapidly in each albumin-containing preparation. Figure 4 shows the viability of S. marcescens and B. cepacia at 30°C in fat emulsions and propofol. Rapid proliferation of these species was also observed in these preparations. 
RESULTS

DISCUSSION
S. marcescens and B. cepacia readily contaminate medical preparations, they are opportunistic bacteria that have been linked to the outbreak of infections in hospitals, and these infections must be taken seriously. [5] [6] [7] [8] [9] [10] [11] P. aeruginosa, S. aureus, and C. albicans are typical pathogenic organisms and often contaminate medical preparations when prepared or manipulated in hospital. 5, 9, 10) We evaluated the viability of these bacteria in preparations packaged for single use only. These bacterial species proliferated rapidly at 30°C in albumin preparations, preparations containing albumin (such as urokinase and interferon), fat emulsions, and a preparation containing fat emulsion (propofol) (Figs. 1, 3, 4) . Infection due to the use of these preparations in multidose vials has often been reported. [12] [13] [14] [15] [16] [17] Therefore package inserts have instructed that residual solution should be discarded after the package has been used.
On the other hand, globulin preparations packaged for single use only could be classified into two groups in which S. marcescens and B. cepacia did and did not proliferate rapidly at 30°C. S. marcescens and B. cepacia proliferated rapidly in globulin preparations that did not contain glycine, whereas no growth of these bacteria was observed over 24 h in globulin preparations containing 1-2.25% glycine (Fig. 2) . The original purpose of the addition of glycine to globulin preparations was to prevent protein degradation. In addition, an inhibitory effect on bacterial proliferation can also be expected. More than 1% concentrations of glycine are antibacterial by impairing transpeptidization within the cell wall. Decreased peptidoglycan subunit synthesis and/or crosslinking results in spheroplast formation and subsequent lysis of both gramnegative and gram-positive bacteria. 18) In the food industry, glycine is widely used as a preservative. 19) To the best of our knowledge, there have been no reports of infection due to the use of globulin preparations in multidose vials. Therefore the warning to "Discard residual solution after the package has been used," in package inserts for globulin preparations containing glycine (Gamma-Venin P, Venilon-I, Globulin Injection, and Ahlbulin) can be changed. Microbial contamination will not occur if residual solution is used within 24 h after the package has been opened for globulin preparations containing glycine. When globulin preparations containing glycine are used in multidose vials, storage in a cool place is mandatory. Microbial proliferation is doubly inhibited by storage in a cool place and the addition of glycine. In terms of the efficient use of limited resources, it is advisable to revise package inserts for globulin preparations containing glycine to state that "It is possible to use residual solution within 24 h after the package has been used when stored in a cool place." 
